Crucial Data Soutions
OCTOBER 21, 2024
Managing and analyzing massive amounts of data from multiple sources is one of the most pressing challenges faced by clinical. The post From Data Silos to Unified Insights: The Power of AI in Clinical Trials appeared first on Crucial Data Solutions.
Bio Pharma Dive
OCTOBER 21, 2024
Immunotherapy and precision medicine show promise in better fighting cancer. What else does the research tell us?
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
OCTOBER 21, 2024
This trial investigated the potential of Nanoscope Therapeutics' MCO-010 to restore vision in patients with retinitis pigmentosa (RP).
Bio Pharma Dive
OCTOBER 21, 2024
Learn how Syngene’s integrated strategy can enhance your mAb production capabilities.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Pharmaceutical Technology
OCTOBER 21, 2024
Astellas Pharma has received approval from the FDA for VYLOY in conjunction with chemotherapy, for the treatment of advanced gastric cancer.
Bio Pharma Dive
OCTOBER 21, 2024
Launched by PureTech and backed by well-known venture capital firms, the startup has raised $325 million since its debut this spring.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Bio Pharma Dive
OCTOBER 21, 2024
Shares in the Boston-based biotech creator, which had a standout success in forming Karuna Therapeutics, trade around cash levels — a "huge value disconnect" its leaders are trying to bridge.
Fierce Pharma
OCTOBER 21, 2024
As Novo Nordisk’s injectable diabetes-obesity duo Ozempic and Wegovy grab all the limelight, an oral version of the semaglutide drug showed it can provide heart-related benefits, too. | As Novo Nordisk’s injectable diabetes-obesity duo Ozempic and Wegovy grab all the limelight, an oral version of the semaglutide drug showed it can provide heart-related benefits, too.
Bio Pharma Dive
OCTOBER 21, 2024
Under the proposed deal, the PE firm would take a controlling 50% stake in Sanofi’s Opella unit, with state-owned Bpifrance taking a minority 2% position.
Pharmaceutical Technology
OCTOBER 21, 2024
As a companion diagnostic, Oncomine will be used to identify patients eligible for treatment with Servier’s Voranigo.
Bio Pharma Dive
OCTOBER 21, 2024
The medicine, which Novo sells as Rybelsus, cut the risk of cardiovascular complications by 14% when added to standard therapies in people with diabetes and heart disease.
Pharmaceutical Technology
OCTOBER 21, 2024
The funding will support Seaport’s technology platform, which helps drugs be absorbed more efficiently through the lymphatic system.
Bio Pharma Dive
OCTOBER 21, 2024
After initially declaring the shortage of Eli Lilly’s diabetes and weight loss drugs over, the FDA has re-opened the door for GLP-1 compounders.
Pharmaceutical Technology
OCTOBER 21, 2024
Arcutis Canada, has received Health Canada's approval for ZORYVE to treat seborrheic dermatitis in patients aged nine years and above.
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
pharmaphorum
OCTOBER 21, 2024
An antiretroviral combination developed by Gilead and MSD suppressed HIV with a single weekly oral dose in a phase 2 trial reported at IDWeek 2024
Pharmaceutical Technology
OCTOBER 21, 2024
A stake by France-owned Bpifrance and promise of local job retention have allayed political backlash over the sale of Sanofi’s consumer health business.
Fierce Pharma
OCTOBER 21, 2024
Sanofi is now in “exclusive negotiations” with U.S. | Sanofi is now in “exclusive negotiations" with U.S. private equity firm Clayton, Dubilier & Rice to sell a 50% controlling stake in its consumer health business Opella, the company said. The deal values the consumer group at 16 billion euros.
Pharmaceutical Technology
OCTOBER 21, 2024
A partial hold was placed on the trial after results showed variance between squamous and non-squamous NSCLC patient responses.
Rethinking Clinical Trials
OCTOBER 21, 2024
Updated study snapshots and ethics and regulatory documentation are now available for the BEST-ICU and Chat 4 Heart Health trials. Both of these NIH Collaboratory Trials are supported by awards from the National Heart, Lung, and Blood Institute. BEST-ICU transitioned from the planning phase to the implementation phase during the summer. As part of the transition, the study team reviewed and updated the minutes of their initial consultation with the Ethics and Regulatory Core.
Pharmaceutical Technology
OCTOBER 21, 2024
In an exclusive interview, the CEO of ImmunoPrecise Antibodies described the benefits of rabbit monoclonal antibodies in oncology.
Pharma Times
OCTOBER 21, 2024
Primary open-angle glaucoma affects around 2% of adults aged 40 years and older in the UK
pharmaphorum
OCTOBER 21, 2024
Two digital therapeutics for addiction are available again through PursueCare, which acquired them from now-defunct Pear Tx last year
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
Pharma Times
OCTOBER 21, 2024
The five new programmes are designed to fit alongside full-time work and clinical practice
pharmaphorum
OCTOBER 21, 2024
Seaport Therapeutics completes a $225m Series B to fund its improved therapies for depression and anxiety, just months after raising $100m on its debut
Velocity Clinical Research
OCTOBER 21, 2024
At the beginning of September, Velocity Clinical Research topped Business North Carolina ’s 2024 Fast 40 list. It was our third time receiving the award, which recognizes the fastest-growing mid-market businesses in the state. For a clinical trials organization to achieve this level of scale is notable. The clinical trials sector in the US is typically made up of small independent businesses that collectively play an important role in trialing new protocols and aiding drug development.
Drug Patent Watch
OCTOBER 21, 2024
The pharmaceutical industry is a significant contributor to the global economy, with a substantial portion of its production costs incurred during the development stage. This makes intellectual property protection crucial for the industry’s success.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Fierce Pharma
OCTOBER 21, 2024
Activist investor Starboard Value, which picked up a $1 billion stake in Pfizer earlier this month, now reportedly has Johnson & Johnson’s consumer health spinout Kenvue in its sights. | Starboard, which recently pitched turnaround plans to Pfizer, reportedly thinks the J&J consumer health spinout's stocks have underperformed since its market debut over a year ago.
pharmaphorum
OCTOBER 21, 2024
Novo Nordisk's TFPI drug concizumab has been backed for approval in the EU to prevent bleeding episodes in people with haemophilia and inhibitors
Fierce Pharma
OCTOBER 21, 2024
After calling for a major discount for Pfizer’s popular transthyretin amyloid cardiomyopathy (ATTR-CM) med tafamidis, a U.S. | After calling for a major discount for Pfizer’s popular transthyretin amyloid cardiomyopathy (ATTR-CM) med tafamidis, a U.S. drug cost watchdog has provided a final analysis that includes a smaller—yet still hefty—price reduction demand.
Drug Channels
OCTOBER 21, 2024
Informa Connect’s Trade and Channel Strategies December 10-12, 2024 at the W Hotel in Philadelphia, PA Drug Channels readers save 10% with code 24DC10 * Pharmacy and distribution models are growing increasingly complex. Stop running in circles—It’s time to unlock proven strategies to propel market access. What is the secret to success? Trade and Channel Strategies is bringing together industry experts to deliver specific strategies and talk best practices in tackling the latest industry challeng
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Expert insights. Personalized for you.
52 
Let's personalize your content